Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Jan;73(1):466.
doi: 10.1002/hep.31439. Epub 2020 Dec 7.

Letter to the Editor: Re: Tenofovir Versus Entecavir on Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma After Surgical Resection

Beom Kyung Kim  1   2 , Seung Up Kim  1   2
Affiliations
Comment

Letter to the Editor: Re: Tenofovir Versus Entecavir on Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma After Surgical Resection

Beom Kyung Kim et al. Hepatology. 2021 Jan.
No abstract available

PubMed Disclaimer

Comment in

  • REPLY.
    Choi J, Lim YS. Choi J, et al. Hepatology. 2021 Jan;73(1):467. doi: 10.1002/hep.31438. Epub 2020 Dec 7. Hepatology. 2021. PMID: 32598515 No abstract available.

Comment on

References

    1. Choi J, Jo C, Lim YS. Tenofovir vs. entecavir on recurrence of hepatitis b virus-related hepatocellular carcinoma after surgical resection. Hepatology 2020 Apr 23. https://doi.org/10.1002/hep.31289. [Epub ahead of print]
    1. Kim SU, Seo YS, Lee HA, Kim MN, Lee YR, Lee HW, et al. A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in South Korea. J Hepatol 2019;71:456-464.
    1. Lee SW, Kwon JH, Lee HL, Yoo SH, Nam HC, Sung PS, et al. Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naïve patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis. Gut 2019 Oct 31. https://doi.org/10.1136/gutjnl-2019-318947. [Epub ahead of print]
    1. Su F, Berry K, Ioannou GN. No difference in hepatocellular carcinoma risk between chronic hepatitis B patients treated with entecavir versus tenofovir. Gut 2020 Mar 30. https://doi.org/10.1136/gutjnl-2019-319867. [Epub ahead of print]

MeSH terms